Design of a novel interleukin-13 antagonist from analysis of informational structure

Biochemistry (Mosc). 2009 Apr;74(4):399-405. doi: 10.1134/s0006297909040075.

Abstract

Interleukin-13 (IL-13) is one of the cytokines involved in the development of Th2-type immune response. It plays an important role in the pathogenesis of asthma and other allergic diseases. Two deletion forms of IL-13 were constructed on a basis of informational structure analysis and expressed in E. coli cells. They were found to differ in ability to stimulate proliferation of TF-1 cell line. Deletion variant 146 (DV146) completely lacks such activity, whereas DV148 provides about 50% of the proliferation stimulation. The simultaneous addition of DV146 with full-length IL-13 suppresses proliferation depending on the concentration of the deletion form. Thus, the designed protein acts as an antagonist of IL-13.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Design*
  • Humans
  • Interleukin-13 / antagonists & inhibitors*
  • Interleukin-13 / chemistry*
  • Interleukin-13 / genetics
  • Interleukin-13 / metabolism
  • Molecular Conformation
  • Molecular Sequence Data
  • Sequence Deletion

Substances

  • Interleukin-13